Astrana Health (ASTH) vs Genpact (G)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Astrana Health (ASTH) has outperformed Genpact (G) over the past year, gaining 28.4% versus a loss of 6.4%. Over five years, G leads with a -15.3% price change compared with -69.4% for ASTH. Genpact is the larger company by market cap ($6.94 billion vs $1.44 billion), about 4.8 times the size, while Astrana Health is growing revenue faster (+56.4% vs +6.6%).
On valuation, Astrana Health trades at a lower forward P/E (8.3x vs 9.2x for Genpact). Genpact pays a dividend yielding 1.77%, while Astrana Health does not currently pay one. Genpact converts more of its revenue into profit, with a net margin of 10.9% versus 0.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | G |
|---|---|---|
| Share price | $28.90 | $41.50 |
| Market cap | $1.44B | $6.94B |
| 1-day change | +0.77% | +1.62% |
| YTD return | +16.49% | -11.29% |
| 1-year return | +28.44% | -6.45% |
| 5-year return | -69.44% | -15.31% |
| P/E ratio (TTM) | 26.76 | 12.10 |
| Forward P/E | 8.30 | 9.16 |
| EPS (TTM) | $1.08 | $3.43 |
| Dividend yield | 0.00% | 1.77% |
| Annual dividend | $0.00 | $0.733 |
| Revenue (latest FY) | $3.18B | $5.08B |
| Revenue growth (YoY) | +56.39% | +6.56% |
| Net income (latest FY) | $22.49M | $552.49M |
| Gross margin | 10.73% | 36.04% |
| Operating margin | 2.47% | 14.77% |
| Net margin | 0.71% | 10.88% |
| 52-week high | $51.60 | $48.64 |
| 52-week low | $18.08 | $26.85 |
| Distance from 52-week high | -43.99% | -14.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +79.55% | +14.80% |
| Average volume | 377.18K | 2.00M |
| Shares outstanding | 49.67M | 167.23M |
| Employees | 3,000 | 142,000 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Professional Services | Professional Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genpact is about 4.8 times larger than Astrana Health by market value ($6.94B vs $1.44B).
- ASTH has outperformed G by 34.9 percentage points over the past year.
- Astrana Health trades at a higher earnings multiple (26.8x vs 12.1x trailing P/E).
- Genpact offers a meaningfully higher dividend yield (1.77% vs 0.00%).
- Genpact is more profitable, keeping 10.9 cents of every revenue dollar as net income versus 0.7 cents for Astrana Health.
- Astrana Health grew revenue faster in its latest fiscal year (+56.39% vs +6.56%).
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About Genpact
G stock →Genpact Limited, an agentic and advanced technology solutions company, provides digital transformation, business process management, technology, data, analytics, and artificial intelligence (AI) services to enterprises in India, the rest of Asia, North and Latin America, and Europe. Its Financial Services segment offers customer onboarding, customer service, collections, retail and commercial loan operations, payment operations, mortgage origination and servicing, compliance, wealth management, capital market operations support, financial crime and risk management, proprietary insurance policy suite, underwriting support, new business processing, policy administration, customer, claims management, catastrophe and exposure/risk modeling, actuarial services, end-to-end third-party administration for property and casualty claims, and technology services.
Consumer Discretionary · Professional Services · 142,000 employees
ASTH vs G FAQ
Which is bigger, Astrana Health or Genpact?
Genpact (G) is larger, with a market capitalization of $6.94B compared with $1.44B for Astrana Health (ASTH).
Which stock has performed better over the past year, ASTH or G?
ASTH returned +28.44% over the past 12 months, compared with -6.45% for G (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASTH or G?
G has the lower trailing P/E at 12.1, versus 26.8 for ASTH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Astrana Health or Genpact?
Genpact pays a dividend yielding 1.77%, while Astrana Health does not currently pay a regular dividend.
Are Astrana Health and Genpact in the same industry?
Yes. Both are classified in the Professional Services industry within the Consumer Discretionary sector.